All In Biotech

NDA 016812 · Ph Health

Ketalar

Ketamine Hydrochloride · Injection

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1970

Feb 19, 1970

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,644

253 Phase 3, 181 recruiting

FAERS reports

5,133

3,592 serious, 562 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 2, 2026.

KETALAR (ketamine hydrochloride) injection is indicated: as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. for the induction of anesthesia prior to the administration of other general anesthetic agents. as a supplement to other anesthetic agents. KETALAR is a general anesthetic indicated: as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation (1) for the induction of anesthesia prior to the administration of other general anesthetic agents (1) as a supplement to other anesthetic agents (1).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 11, 1982 Supplement 23 · Efficacy
  • Feb 19, 1970 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
  • KETALAR · KETAMINE HYDROCHLORIDE EQ 10MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • KETALAR · KETAMINE HYDROCHLORIDE EQ 50MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP
  • KETALAR · KETAMINE HYDROCHLORIDE EQ 100MG BASE/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ketamine" as an intervention, any sponsor and status, largest first.

All 1,644 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • infusion site pain797
  • drug ineffective564
  • nausea545
  • off label use539
  • infusion site erythema501
  • infusion site swelling347
  • headache342
  • diarrhoea317
  • drug abuse315
  • dyspnoea313
  • hyperhidrosis238
  • fatigue237

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200420
200520
20065
200735
200828
200959
201094
201161
201283
201384
2014104
201594
2016114
201784
201864
2019143
2020114
2021194
2022240
2023563
20241,079
20251,106
2026744

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,511 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.